Keros Therapeutics reports Q2 2024 net loss of $45.3M; cash runway into 2027

Keros Therapeutics, Inc.

2024-Q2 EPS reported -$2.46

Net loss of $45.3M in Q2 2024, up from $37.5M in Q2 2023 due to increased R&D spend.
R&D expenses $40.5M (Q2 2024) vs $32.5M (Q2 2023); G&A $10.0M vs $8.8M.
Cash and equivalents $405.9M as of June 30, 2024, expected to fund operations into 2027.
Elritercept (KER-050) positive regulatory/data updates; cibotercept (KER-012) Phase 2 PAH enrollment to complete Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.